Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Health-Related Legislation

July 1, 1995
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

S5755, an amendment (no. 603) introduced by Sen. McConnell (R-KY), to reform the health-care liability system and improve health-care quality through establishment of quality assurance programs, was agreed to by voice vote.

  • S5755, an amendment (no. 603) introduced by Sen. McConnell(R-KY), to reform the health-care liability system and improvehealth-care quality through establishment of quality assuranceprograms, was agreed to by voice vote.
  • S5793, an amendment (no. 605) introduced by Sen. Wellstone(D-MN), to revise provisions regarding reports on medical malpracticedata and access to certain information, was tabled by voice vote.
  • S5800, an amendment (no. 608) introduced by Sen. Snowe (R-ME),to limit the amount of punitive damages that may be awarded ina health-care liability action, was agreed to by voice vote.
  • S5931, an amendment (no. 611) introduced by Sen. Kyl (R-AZ),to place a limitation of $500,000 on noneconomic damages thatare awarded to compensate a claimant for pain, suffering, emotionaldistress, and other related injuries, was tabled by voice vote.
  • H1566, a bill to amend the Internal Revenue Code to make permanentthe credit for clinical testing expenses for certain drugs andrare diseases or conditions was introduced by Rep. Johnson (R-CT).
Articles in this issue

ODAC Recommends Accelerated FDA Approval of Ethyol for Cytoprotection
House Panel Holds Hearing on Self-Referral
Health-Related Legislation
Mitoguazone Appears Promising in HIV-Associated Refractory NHL
Responses to Anti-HER2 MoAb Seen
NCI Committed to Increasing Minority Participation in Clinical Trials
MoAb May Improve Detection of Colon And Rectal Cancer
Zeneca Files NDA for Arimidex
Cord Blood is Used as Source of Stem Cells for Pediatric Transplantation
Gemcitabine/Cisplatin Shows Good Response Rate And Favorable Toxicity Profile in Advanced NSCLC
HCFA Needs to Do More to Prevent Medicare/Medicaid Fraud and Abuse
M.D. Anderson Holds First Cancer Meeting in Spanish
Molecular Markers Predict Clinical Outcome
NCAB Has Concerns About Future of Clinical Research
IP Interleukin-2 Shows Durable Responses in Ovarian Cancer
Recent Videos
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
2 KOLs are featured in this series.
Related Content
Advertisement

Laser vision correction. A patient and team of surgeons in the operating room during ophthalmic surgery. Eyelid speculum. Lasik treatment.| Image Credit: © romaset-stock.adobe.com

Brachytherapy/Vitrectomy, Silicone Oil Confer Positive Uveal Melanoma DMFS

Ariana Pelosci
September 28th 2025
Article

An 80% disease metastasis-free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

ONCOLOGY Staff
September 27th 2025
Article

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Ziftomenib Shows Significant Benefit in Relapsed/Refractory NPM1+ AML

Russ Conroy
September 26th 2025
Article

Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.


Following over a decade of oversight, no cases of Torsades de pointes or unexplained sudden deaths were reported among US patients who received vandetanib in REMS assessments.

FDA Drops REMS Requirement for Vandetanib in Medullary Thyroid Cancer

Tim Cortese
September 26th 2025
Article

Physicians are no longer required to have special certification to administer vandetanib to patients with medullary thyroid cancer.

Related Content
Advertisement

Laser vision correction. A patient and team of surgeons in the operating room during ophthalmic surgery. Eyelid speculum. Lasik treatment.| Image Credit: © romaset-stock.adobe.com

Brachytherapy/Vitrectomy, Silicone Oil Confer Positive Uveal Melanoma DMFS

Ariana Pelosci
September 28th 2025
Article

An 80% disease metastasis-free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

ONCOLOGY Staff
September 27th 2025
Article

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Ziftomenib Shows Significant Benefit in Relapsed/Refractory NPM1+ AML

Russ Conroy
September 26th 2025
Article

Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.


Following over a decade of oversight, no cases of Torsades de pointes or unexplained sudden deaths were reported among US patients who received vandetanib in REMS assessments.

FDA Drops REMS Requirement for Vandetanib in Medullary Thyroid Cancer

Tim Cortese
September 26th 2025
Article

Physicians are no longer required to have special certification to administer vandetanib to patients with medullary thyroid cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.